{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalComment":"Stratified by Previous biologic agent and/or JAK inhibitors exposure, Use of oral corticosteroids treatment at Week 0, Clinical remission at Week 10.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"description":"Clinical remission was defined as an absolute Crohn's Disease Activity Index (CDAI) score of \\<150 points.\n\nThe total CDAI scores range from 0 to over 600 with higher scores indicating increased severity of disease. The index is the sum of 8 components; number of liquid or very soft stools, abdominal pain, general well-being, CD complications, taking antidiarrheal drugs, abdominal mass, hematocrit, and weight.\n\nPatients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-remitter.","groups":[{"description":"CT-P13 SC 120 mg","id":"OG000","title":"CT-P13 SC 120 mg"},{"description":"Placebo","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All-randomized population","reportingStatus":"POSTED","timeFrame":"Week 54","title":"Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54","type":"PRIMARY","unitOfMeasure":"Participants"}